DEVELOPING THE NEXT GENERATION OF MEDICINES THAT TARGET AND ENHANCE THE MICROBIOME Groundwork laid for a future of cultured microbiome therapies targeting specific diseases
INTERVIEW
Associate Professor Sam Forster, CSL Centenary Fellow, Research Group Head
Microbiota and Systems Biology, Hudson Institute of Medical Research
& Team Leader, Australian Microbiome Culture Collection
& Chief Scientific Officer, BiomeBank
Dr Sam Costello,
Co-founder & CEO
BiomeBank
SEGMENT
Filmed in Melbourne and Adelaide | December 2024
Australian Health Journal spoke to Associate Professor Sam Forster, Research Group Head, Microbiota and Systems Biology, Hudson Institute of Medical Research, Team Leader, Australian Microbiome Culture Collection & Chief Scientific Officer, BiomeBank and Dr Sam Costello, Co-Founder and CEO of BiomeBank about the microbiome, partnering and some of the breakthroughs in recent years.
Assoc Prof Forster describes the role of the microbiome, “Every one of us carries thousands of bacteria. Millions of individual cells, and they’re intimately associated with all sorts of sites on our bodies. So our gut is the most common place we think about, but our lungs, our skin, everywhere. Where there’s an interface, the external environment, there’s bacteria and other microbes that actually enable us to interface with the external world. They detect changes and they regulate our immune response.”
This can be really important from a health perspective because they indicate when things are going well, we should have a healthy state or something’s gone wrong, and there is an inflammatory response. This can then be detrimental, or it can help clear a particular condition.
“The microbes we carry are intimately associated with our health.”, says Assoc Prof Forster. He was the founder of the Australian Microbiome Culture Collection at Hudson that now contains over 40,000 bacterial isolates. This provides a resource for further research.
“All of these opportunities are available because we have this vast collection of microbes where we can say this particular combination for you is relevant for this experiment. Taking clinical samples, we then can replicate the host environment using microfluidic organ on-a-chip systems”, says Assoc Prof Forster.
Microbiome therapies involve modifying the body’s microbial communities to improve health. These treatments aim to restore balance to the microbiome, potentially alleviating conditions like inflammatory bowel disease, liver disorders, autoimmune diseases, and certain cancers.
The Hudson Institute of Medical Research and BiomeBank have partnered to advance microbiome-based therapeutics. Their collaboration focuses on identifying key bacteria involved in disease onset and resolution, particularly associated with the gut. By combining their expertise, they aim to develop targeted microbial therapies to treat and prevent diseases by restoring gut microbial ecology.
BiomeBank develops and delivers microbiome therapies. In 2022 BiomeBank was successful in introducing the world’s first approved donor derived microbiome therapy approved in Australia for the treatment of C. Difficile infection.
Through this collaboration, the Hudson Institute and BiomeBank are at the forefront of microbiome research, striving to translate scientific discoveries into effective therapies that can improve patient outcomes.
As Dr Costello states, “We see microbiome therapies evolving in the next few years from predominantly donor derived therapies that are harvested from screened healthy stool donors, towards cultured therapies that can be grown in bioreactors and produced under controlled conditions.”
Assoc Prof Forster has been involved in a number of breakthroughs in culturing previously thought to be unculturable organisms.
-
CASE STUDY: Creating awareness, workforce education & dissemination strategy in national screening
At the recent Screening Conference 2025 in Sydney, hosted by Public Health Association, Dr Rachael Dodd, Senior Research Fellow at The Daffodil Centre, spoke about the information and educational resources created to increase awareness in the healthcare workforce and community on the upcoming Australia’s National Lung Cancer Screening Program commencing in July 2025.
-
Bionic eye trial shows improvements in functional vision for retinitis pigmentosa
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, the trial findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
-
Physiotherapist, exercise physiologist support for management of osteoporosis
Osteoporosis is commonly managed medically and typically with treatment. Exercise is also essential in the management of osteoporosis but tends to be under-utilised due to lack of knowledge and unfounded concerns about the risk of injury. In fact, optimal care of people with low bone mass, osteoporosis and/or increased risk of falling can and should include targeted exercise to help prevent osteoporotic fracture.
In early 2024, Healthy Bones Australia released a summary of the principles of osteogenic loading and fall prevention, the translation of those principles into clinical practice, evidence-based recommendations for exercise prescription, and special considerations, along with links to several relevant resources for people with or at risk of osteoporosis, falls and fractures.
